- Conditions
- Advanced Solid Tumors
- Interventions
- paclitaxel, FOLFIRI, ABT-165, ABBV-181
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2065–2088
of 3,057
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer
- Interventions
- Colonoscopy, Fecal immunochemical test (FIT)
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 50,126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more
- Conditions
- Colorectal Cancer
- Interventions
- mt-sDNA 2.0 screening test, FIT test, Colonoscopy
- Diagnostic Test · Procedure
- Lead sponsor
- Exact Sciences Corporation
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 26,758 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 195
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Dothan, Alabama + 161 more
- Conditions
- Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Ovarian Cancer, Endometrial Cancer, Hepatocellular Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Colorectal Cancer, Head and Neck Cancer, Differentiated Thyroid Cancer, Lower Esophageal Cancer
- Interventions
- cabozantinib, atezolizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 57
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Duarte, California + 45 more
- Conditions
- Colorectal Cancer
- Interventions
- Water Exchange Sigmoidoscopy, Air Insufflation Sigmoidoscopy
- Procedure
- Lead sponsor
- Kelowna Gastroenterology Associates
- Other
- Eligibility
- 50 Years to 74 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- North Hills, California
- Conditions
- Breast Cancer, Colorectal Cancer, Covid19
- Interventions
- Informational videos and social media campaigns encouraging cancer screening.
- Behavioral
- Lead sponsor
- Rhode Island Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Pawtucket, Rhode Island
- Conditions
- Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
- Interventions
- rezatapopt, pembrolizumab
- Drug
- Lead sponsor
- PMV Pharmaceuticals, Inc
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Irvine, California • La Jolla, California • Los Angeles, California + 26 more
- Conditions
- Anal Cancer, Colorectal Cancer, Perioperative/Postoperative Complications
- Interventions
- conventional surgery, management of therapy complications
- Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colo-rectal Cancer
- Interventions
- Decision Counseling Session
- Behavioral
- Lead sponsor
- Guardant Health, Inc.
- Industry
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer, Colorectal Cancer (CRC)
- Interventions
- fruquintinib, FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 14
- States / cities
- Denver, Colorado • Arlington Heights, Illinois • Columbia, Maryland + 11 more
- Conditions
- Metastatic Colorectal Cancer (CRC)
- Interventions
- Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
- Drug
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 900 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 112
- States / cities
- Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 94 more
- Conditions
- Advanced Colorectal Adenocarcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Interventions
- Balstilimab, Biospecimen Collection, Botensilimab, Computed Tomography, Regorafenib
- Biological · Procedure · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Colorectal Cancer
- Interventions
- Observation
- Other
- Lead sponsor
- Tempus AI
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 20
- States / cities
- Fort Smith, Arkansas • Fountain Valley, California • Bethesda, Maryland + 14 more
- Conditions
- Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Urothelial Cancer, Melanoma
- Interventions
- PF-07329640, sasanlimab, bevacizumab
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 4
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 1 more
- Conditions
- Breast Neoplasms, Ovarian Neoplasms, Colonic Neoplasms, Prostatic Neoplasms, Uterine Cervical Neoplasms, Leukemia, Lymphoma, Non-Hodgkin
- Interventions
- Not listed
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 992 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
- Interventions
- PF-08052666
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
- Conditions
- Cancer, Cancer Diagnosis, Early Detection of Cancer, Breast Cancer, Lung Cancer, Colon Cancer, GI Cancer, Gynecologic Cancer, Ovarian Cancer, Endometrial Cancer, CNS Cancer, Hematologic Cancer
- Interventions
- Not listed
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25,000 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Marshall, Minnesota • Aberdeen, South Dakota • Mitchell, South Dakota + 3 more
- Conditions
- Colorectal Cancer
- Interventions
- rubitecan
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 1
- States / cities
- Dublin, California
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Interventions
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine, Pneumococcal Vaccine, Hepatitis A Vaccine, Hepatitis B Vaccine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 60 Years to 100 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • New York, New York
- Conditions
- NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer), ES-SCLC, Small Cell Lung Cancer Extensive Stage, B7H3, Prostate Cancer, HNSCC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Head Neck Cancer Squamous Cell Metastatic, ESCC or Esophageal Adenosquamous Carcinoma, CRC, CRC (Colorectal Cancer)
- Interventions
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Drug
- Lead sponsor
- Aktis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Miami, Florida • Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- Fecal immunochemical test (FIT)
- Device
- Lead sponsor
- Barcey T. Levy
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 3,761 participants
- Timeline
- 2017 – 2023
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Chapel Hill, North Carolina • El Paso, Texas
- Conditions
- Microsatellite Stable Relapsed or Refractory Colorectal Cancer
- Interventions
- eFT508, Avelumab
- Drug
- Lead sponsor
- Effector Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Sarasota, Florida + 4 more
- Conditions
- Colorectal Carcinoma
- Interventions
- VELCADE TM (bortezomib) for Injection, or PS-341
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Pine Bluff, Arkansas + 18 more
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Interventions
- INCA00186, Retifanlimab, INCB106385
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 5 more